Finding new ways to stop breast cancer from spreading
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
This research aims to discover new medicines that can specifically target and stop breast cancer from spreading to other parts of the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11128807 on NIH RePORTER |
What this research studies
We know that cancer spreading, or metastasis, is a major challenge in treating breast cancer, and current treatments often don't fully address it. This project takes a fresh approach by looking at unique features within cancer cells that are linked to their ability to spread. By identifying these specific features, we hope to find new drug candidates that can selectively block the metastatic process. Our goal is to develop more effective treatments that can improve long-term outcomes for patients.
Who could benefit from this research
Good fit: This foundational research is for patients with breast cancer, especially those at risk of or experiencing metastasis, who may benefit from future therapies developed from this work.
Not a fit: Patients without breast cancer or those whose cancer is not metastatic would not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective medications specifically designed to prevent or treat breast cancer metastasis, potentially improving patient survival.
How similar studies have performed: While current anti-cancer agents have shown success in treating primary tumors, effective treatments specifically targeting metastasis remain a significant challenge, making this approach novel.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Huang, Sui — Northwestern University
- Study coordinator: Huang, Sui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.